Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia

✍ Scribed by Steven P. Treon; Guang Yang; Christine Hanzis; Leukothea Ioakimidis; Sigitas J. Verselis; Edward A. Fox; Lian Xu; Zachary R. Hunter; Hsiuyi Tseng; Robert J. Manning; Christopher J. Patterson; Patricia Sheehy; Barry Turnbull

• Book ID: 108677306
• Publisher: John Wiley and Sons
• Year: 2011
• Tongue: English
• Weight: 130 KB
• Volume: 154
• Category: Article
• ISSN: 0007-1048
• DOI: 10.1111/j.1365-2141.2011.08726.x